Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Receives Consensus Recommendation of “Hold” from Analysts

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has been given a consensus recommendation of “Hold” by the seven ratings firms that are presently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $61.60.

A number of equities research analysts recently commented on SUPN shares. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Monday, December 29th. Zacks Research cut shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 29th. Bank of America initiated coverage on shares of Supernus Pharmaceuticals in a research note on Wednesday, October 29th. They issued a “buy” rating and a $65.00 price objective on the stock. Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 31st. Finally, TD Cowen upped their price target on shares of Supernus Pharmaceuticals from $45.00 to $60.00 and gave the company a “buy” rating in a report on Thursday, October 23rd.

Insider Transactions at Supernus Pharmaceuticals

In other news, VP Padmanabh P. Bhatt sold 710 shares of the firm’s stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $44.44, for a total transaction of $31,552.40. Following the sale, the vice president owned 14,508 shares of the company’s stock, valued at $644,735.52. This trade represents a 4.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Frank Mottola sold 20,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $50.41, for a total transaction of $1,008,200.00. Following the transaction, the senior vice president directly owned 15,496 shares of the company’s stock, valued at approximately $781,153.36. This trade represents a 56.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 8.80% of the stock is owned by corporate insiders.

Institutional Trading of Supernus Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Hantz Financial Services Inc. boosted its stake in shares of Supernus Pharmaceuticals by 81.7% during the 3rd quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock worth $30,000 after acquiring an additional 281 shares in the last quarter. Torren Management LLC purchased a new position in Supernus Pharmaceuticals during the fourth quarter worth approximately $49,000. USA Financial Formulas acquired a new stake in Supernus Pharmaceuticals in the third quarter valued at approximately $50,000. Smartleaf Asset Management LLC grew its holdings in Supernus Pharmaceuticals by 30.8% in the third quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock valued at $54,000 after purchasing an additional 268 shares during the period. Finally, Global Retirement Partners LLC increased its position in shares of Supernus Pharmaceuticals by 532.4% in the fourth quarter. Global Retirement Partners LLC now owns 1,404 shares of the specialty pharmaceutical company’s stock valued at $70,000 after buying an additional 1,182 shares in the last quarter.

Supernus Pharmaceuticals Trading Down 0.7%

NASDAQ SUPN opened at $51.30 on Thursday. The company has a fifty day simple moving average of $49.25 and a two-hundred day simple moving average of $46.98. The stock has a market cap of $2.94 billion, a P/E ratio of -150.88, a P/E/G ratio of 0.65 and a beta of 0.71. Supernus Pharmaceuticals has a 12-month low of $29.16 and a 12-month high of $57.65.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.